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Recent	  discoveries	  on	  the	  pathogenesis	  and	  symptom	  structure	  of	  autism	  spectrum	  disorders	  (ASD)	  are	  
challenging	  traditional	  nosology,	  and	   invoke	  consideration	  of	  a	  reconceptualization	  of	  diagnosis,	  made	  
all	  the	  more	  pressing	  by	  new	  prospects	  for	  early	   identification,	  targeted	  intervention	  and	  personalized	  
medicine	   approaches	   to	   specific	   autistic	   syndromes.	   Here	  we	   review	   key	   strengths	   and	   limitations	   of	  
current	   standards	   for	   diagnosis,	   clarifying	   the	   relationship	   between	   current	   diagnostic	   thresholds	   and	  
2	  
	  
what	   is	   now	   known	   about	   the	   structure	   of	   symptoms	   in	   nature,	   assimilate	   recent	   advances	   in	  
understanding	   about	   the	   diversity	   of	   causes	   of	   autistic	   syndromes,	   and	   finally	   propose	   ways	   for	  
knowledge	   of	   causation	   and	   symptom	   structure	   to	   be	   incorporated	   into	   the	   next	   evolution	   in	   the	  
approach	  to	  diagnosis	  of	  autism.	  
I. Introduction:	  The	  Shifting	  Landscape	  of	  Contemporary	  Clinical	  Diagnosis	  
	  	  
Until	   about	   a	   decade	   ago,	   autism	   was	   rare,	   usually	   accompanied	   by	   intellectual	   disability,	   lacked	  
standardized	  methods	  for	  calibrating	  the	  ascertainment	  of	  symptoms,	  and	  only	  rarely	  could	  be	  traced	  to	  
a	  biological	  cause.	  All	  of	  that	  has	  changed.	  And	  although	  clinician	  diagnosis	  maintains	  its	  tentative	  hold	  
as	   the	   current	   standard	   for	   case	   designation,	   that	   standard	   is	   increasingly	   informed	   by	   a	   steady	  
progression	   of	   scientific	   discoveries	   that	   have	   challenged	   traditional	   perspectives	   on	   the	   appropriate	  
threshold	  for	  assigning	  a	  clinical	  diagnosis	  and	  on	  how	  diagnosis	  should	  relate	  to	  the	  specific	  cause	  of	  an	  
autism	  spectrum	  disorder	  (ASD)	  in	  an	  individual	  patient.	  In	  essence,	  in	  each	  of	  Robins	  and	  Guze’s	  classic	  
19701	  proposed	  requirements	  for	  valid	  classification	  of	  mental	  disorders	  (clinical	  description,	  laboratory	  
study,	  exclusion	  of	  other	  disorders,	  follow-­‐up	  study,	  and	  family	  study)	  rapid	  advances	  in	  the	  science	  of	  
autism	  have	  occurred.	  
	  
The	   diagnostic	   implications	   of	   these	   recent	   discoveries,	   especially	   related	   to	   symptom	   structure	   and	  
biological	  cause	  are	  numerous,	  and	  largely	  encompassed	  by	  four	  overarching	  themes	  (1)	  Limitations	  of	  
the	  Expert	  Clinician	  Paradigm	  as	  a	   standard	  of	  diagnosis2,	   (2)	   The	  Quantitative	  Trait	   Characteristics	  of	  
ASD:	   i.e.	   that	   the	  defining	   features	  of	   the	  syndrome	  are	  continuously	   (not	  categorically)	  distributed	   in	  
the	  general	  population,	  and	  that	  they	  often	  arise	  from	  additive	  genetic	  influences	  that	  are	  shared	  with	  
other	  neuropsychiatric	  conditions,3·∙5	  (3)	  Pronounced	  Heterogeneity	  in	  the	  pathways	  of	  causation	  to	  ASD	  
phenocopies6	  even	  within	  families,7	  and	  (4)	  Pleiotropic	  Effects,	  that	  the	  same	  deleterious	  genetic	  variant	  
can	   give	   rise	   to	   various	   neuropsychiatric	   syndromes	   (e.g.	   epilepsy,	   schizophrenia,	   ADHD,	   learning	  
disability,	   intellectual	   disability)	   or	   other	   non-­‐ASD	   comorbidities	   (motor	   coordination	   or	   behavioral	  
impairments)8,9	  depending	   in	  part	  on	  genetic	  background.10	  Some	  or	  all	  of	  these	   issues	  present	  similar	  
challenges	  in	  other	  complex	  medical	  diseases	  (e.g.	  hypertension,	  diabetes,	  inflammatory	  bowel	  disease).	  	  
	  
The	  goal	  of	  this	  article	  is	  to	  assimilate	  the	  specifics	  for	  ASD:	  beginning	  with	  the	  strengths	  and	  limitations	  
of	   current	   standards	   for	   diagnosis	   (invoking	   Theme	   1	   above),	   clarifying	   how	   the	   resulting	   diagnostic	  
thresholds	  relate	  to	  the	  structure	  of	  symptoms	  in	  nature	  (Theme	  2),	  next	  reviewing	  what	  is	  now	  known	  
about	   the	   diversity	   of	   causes	   of	   autistic	   syndromes	   (Themes	   3	   and	   4),	   and	   finally	   how	   knowledge	   of	  
causation	   and	   symptom	   structure	   might	   be	   incorporated	   into	   the	   next	   evolution	   in	   the	   diagnostic	  
approach	  to	  ASD.	  DSM-­‐5	  has	  represented	  a	  partial	  attempt	  to	  modify	  the	  diagnostic	  process	  in	  tandem	  
with	  the	  pace	  of	  recent	  discovery,	  but	  it	  remains	  an	  important	  goal	  to	  continue	  to	  build	  upon	  and	  refine	  
the	  existing	   taxonomic	   framework	   in	   a	  manner	   that	   flexibly	   and	   faithfully	   accommodates	   advances	   in	  





II. Foundational	  Elements	  of	  Contemporary	  Clinical	  Diagnosis	  of	  ASD	  
	  
We	  begin	  with	   the	  paradigm	  for	  clinical	  diagnosis,	  which	   is	   the	  historical	  bedrock	  of	  case	  designation.	  
Panels	  A	  and	  B	   list,	   respectively,	  diagnostic	   criteria	   for	  ASD	  according	   to	   the	  Diagnostic	  and	  Statistical	  
Manual	  5	  (DSM-­‐5)11	  and	  its	  published	  parameters	  for	  specifying	  severity.	  The	  information	  in	  these	  panels	  
reflect	   the	   incorporation	  of	   several	   noteworthy	   scientific	   advances	  over	  DSM-­‐IV	   (we	  note	   that	   ICD-­‐10	  
criteria	   for	  autism	  are	  keyed	   to	  DSM-­‐IV,	   and	  as	  of	   this	  writing	   it	   is	  not	   yet	   resolved	  precisely	   to	  what	  
extent	  ICD-­‐11	  will	  reflect	  the	  changes	  incorporated	  into	  DSM-­‐5).	  First	  is	  that	  the	  symptom	  criteria	  were	  
collapsed	   from	   3	   domains	   to	   2,	   in	   part	   on	   the	   basis	   of	   evidence	   that	   the	   social	   and	   communicative	  
impairments	   that	   are	   most	   specific	   to	   autism	   spectrum	   disorders	   (impairment	   in	   reciprocal	   social	  
interaction	   and	   impairment	   in	   social	   /	   pragmatic	   aspects	   of	   communication)	   are	   closely	   inter-­‐related,	  
and	  their	   severity	  highly	  correlated,	  not	  only	  within	  populations	  of	  clinically-­‐affected	  children,12	  but	   in	  
the	  general	  population3,	  with	  the	  caveat	  that	  results	  of	  factor	  analyses	  of	  ASD	  symptoms	  can	  be	  variable	  
as	   a	   function	   of	   how	   they	   are	   ascertained.	   Second,	   new	   severity	   specifiers	   (Panel	   B)	   categorize	   the	  
Panel A. DSM-5 Diagnostic Criteria for Autism Spectrum Disorder           299.00 (F84.0) 
	  
A.      Persistent deficits in social communication and social interaction across multiple contexts, as manifested by the following, currently or 
by history (examples are illustrative, not exhaustive, see text): 
1.       Deficits in social-emotional reciprocity, ranging, for example, from abnormal social approach and failure of normal 
back-and-forth conversation; to reduced sharing of interests, emotions, or affect; to failure to initiate or respond to social 
interactions. 
2.       Deficits in nonverbal communicative behaviors used for social interaction, ranging, for example, from poorly integrated 
verbal and nonverbal communication; to abnormalities in eye contact and body language or deficits in understanding and 
use of gestures; to a total lack of facial expressions and nonverbal communication. 
3.       Deficits in developing, maintaining, and understanding relationships, ranging, for example, from difficulties adjusting 
behavior to suit various social contexts; to difficulties in sharing imaginative play or in making friends; to absence of interest 
in peers. 
B.      Restricted, repetitive patterns of behavior, interests, or activities, as manifested by at least two of the following, currently or by history 
(examples are illustrative, not exhaustive; see text): 
1.       Stereotyped or repetitive motor movements, use of objects, or speech (e.g., simple motor stereotypies, lining up toys 
or flipping objects, echolalia, idiosyncratic phrases). 
2.       Insistence on sameness, inflexible adherence to routines, or ritualized patterns or verbal nonverbal behavior (e.g., 
extreme distress at small changes, difficulties with transitions, rigid thinking patterns, greeting rituals, need to take same 
route or eat food every day). 
3.       Highly restricted, fixated interests that are abnormal in intensity or focus (e.g., strong attachment to or preoccupation 
with unusual objects, excessively circumscribed or perseverative interest). 
4.       Hyper· or hyporeactivity to sensory input or unusual interests in sensory aspects of the environment (e.g., apparent 
indifference to pain/temperature, adverse response to specific sounds or textures, excessive smelling or touching of objects, 
visual fascination with lights or movement). 
 
C.      Symptoms must be present in the early developmental period (but may not become fully manifest until social demands exceed limited 
capacities, or may be masked by learned strategies in later life). 
D.      Symptoms cause clinically significant impairment in social, occupational, or other important areas of current functioning. 
E.       These disturbances are not better explained by intellectual disability (intellectual developmental disorder) or global developmental 
delay. Intellectual disability and autism spectrum disorder frequently co-occur; to make comorbid diagnoses of autism spectrum disorder 
and intellectual disability, social communication should be below that expected for general developmental level. 
Specify if: 
With or without accompanying intellectual impairment 
With or without accompanying language impairment 
Associated with a known medical or genetic condition or environmental factor 




impact	   of	   symptoms	   on	   adaptive	   functioning.	   An	   often-­‐overlooked	   aspect	   of	   the	   characterization	   of	  
severity	  in	  ASD	  is	  that	  i)	  core	  symptom	  burden	  (DSM-­‐5	  Criteria	  A	  and	  B)	  and	  ii)	  impairment	  in	  adaptive	  
functioning	   (DSM-­‐5	   Criterion	   D)	   are	   each	   quantifiable,	   and	   only	   partially	   correlated;	   there	   are	   many	  
clinical	  situations	  in	  which	  core	  ASD	  symptom	  burden	  is	  pronounced	  but	  impairment	  relatively	  mild,	  and	  
vice	   versa.	   Consider,	   for	   example,	   a	   well-­‐adjusted	   individual	   who	   formerly	   carried	   a	   diagnosis	   of	  
Asperger	  Disorder	  on	  the	  basis	  of	  very	  substantial	  ASD	  symptomatology	  but	  is	  successfully	  employed	  in	  
a	  technical	  field,	  or	  an	  individual	  with	  milder	  ASD-­‐specific	  symptoms	  accompanied	  by	  general	  cognitive	  
impairment	   such	   that	   the	   combination	   results	   in	   profound	   impairment	   in	   adaptive	   functioning.	   Thus	  
symptom	  burden	  and	  impairment	  in	  adaptive	  functioning	  constitute	  orthogonal	  axes	  of	  diagnosis,	  both	  
of	   which	   are	   important	   to	   measure,	   and	   it	   can	   be	   well-­‐argued	   that	   most	   of	   the	   proven	   benefits	   of	  
currently-­‐available	  interventions	  for	  autism	  are	  in	  the	  realm	  of	  adaptive	  functioning,	  not	  core	  symptom	  
counts	  (see	  13·∙15).	  Improvements	  in	  adaptive	  functioning	  are	  achievable	  and	  critical	  for	  patients	  with	  ASD,	  
but	   grossly	   under-­‐appreciated	   when	  measuring	   outcomes	   exclusively	   as	   a	   function	   of	   core	   symptom	  
burden,	  as	  still	  often	  occurs	   in	  clinical	   trials.	  Panel	  B	   represents	   the	  hybrid	  severity	   index	  published	   in	  
DSM-­‐5	   that	   translates	   the	   impact	   of	   symptoms	   in	   each	   criterion	   domain	   (A	   and	   B)	   onto	   three	   broad	  
categories	  of	  adaptive	   functioning,	  each	  of	  which	  are	  defined	  by	  descriptive	  scoring	  anchors	  depicting	  
the	   level	   of	   support	   an	   affected	   individual	   requires.	   Third,	   it	   is	   now	   deemed	   appropriate	   to	  
simultaneously	   diagnose	   ASD	  with	   other	   psychiatric	   or	   developmental	   disorders	  when	   there	   is	   ample	  
evidence	  for	  comorbidity,	  given	  overwhelming	  evidence	  that	  many	  known	  inherited	  causes	  of	  ASD	  are	  
genetically	   independent	   from	  the	  causes	  of	  other	  common	  psychiatric	  conditions,16	  and	  therefore	   it	   is	  




The	  diagnostic	  process	  
Implied,	  but	  not	  explicit	  in	  the	  diagnostic	  criteria	  themselves,	  are	  the	  elements	  of	  information-­‐gathering	  
that	  are	  required	  to	  establish	  diagnostic	  criteria	  A·∙E,	  and	  therefore	  constitute	  what	  can	  be	  thought	  of	  as	  
3	  pillars	  of	  the	  diagnostic	  process:	  	  1)	  ascertainment	  of	  current	  symptomatology	  sufficient	  to	  meet	  the	  
A,	  B,	  and	  D	  criteria,	  2)	  the	  acquisition	  of	  a	  developmental	  history	  consistent	  with	  ASD	  (C,	  provided	  by	  a	  
primary	  caregiver	  of	  the	  child	  whenever	  possible),	  and	  3)	  clinician	  confirmation.	  	  
Since	   the	   severity	   of	   current	   symptomatology	   can	   vary	   as	   a	   function	   of	   environmental	   context	   and	  
demands,	   appraisal	   of	   symptoms	   requires	  caregivers	   and	   teachers	   to	   provide	   accounts	  of	   an	   affected	  
individual’s	   behavior	   in	   the	   social	   environment	   of	   home,	   school,	   and	   community,	   to	   report	   on	   their	  
social	   interests	  and	  peer	  relationships	   (which	  cannot	  be	  ascertained	  on	  exam);	   to	  provide	   information	  
on	   their	   day-­‐to-­‐day	   social	   communication,	   including	   use	   of	   verbal	   and	   non-­‐verbal	   language	   and	  
communication;	   imagination	   and	   play;	   sensory	   responses;	   self-­‐help	   skills;	   mood;	   tantrums	   and	  
outbursts;	   and	   to	   endorse	   the	   presence	   or	   absence	   of	   the	   pathognomonic	   repetitive	   or	   stereotypic	  
behaviors	  of	  ASD	  including	  observations	  of	  rigid	  or	  repetitive	  patterns	  of	  behavior.	  	  
Panel B. Severity Specifiers: Characterizing variation in adaptive functioning in ASD 
Severity level Social communication Restricted, repetitive behaviors 
Level 3 
"Requiring very substantial support” 
  Severe deficits in verbal and nonverbal social 
communication skills cause severe impairments in 
functioning, very limited initiation of social interactions, 
and minimal response to social overtures from others. 
For example, a person with few words of intelligible 
speech who rarely initiates interaction and, when he 
or she does, makes unusual approaches to meet 
needs only and responds to only very direct social 
approaches 
  Inflexibility of behavior, extreme difficulty coping 
with change, or other restricted/repetitive 
behaviors markedly interfere with functioning in all 
spheres. Great distress/difficulty changing focus or 
action. 
  Level 2 
"Requiring substantial support” 
  Marked deficits in verbal and nonverbal social 
communication skills; social impairments apparent 
even with supports in place; limited initiation of social 
interactions; and reduced or abnormal responses to 
social overtures from others. For example, a person 
who speaks simple sentences, whose interaction is 
limited to narrow special interests, and how has 
markedly odd nonverbal communication. 
  Inflexibility of behavior, difficulty coping with 
change or other restricted/repetitive behaviors 
appear frequently enough to be obvious to the 
casual observer and interfere with functioning in a 
variety of contexts. Distress and/or difficulty 
changing focus or action. 
  Level 1 
"Requiring support” 
  Without supports in place, deficits in social 
communication cause noticeable impairments. 
Difficulty initiating social interactions, and clear 
examples of atypical or unsuccessful response to 
social overtures of others. May appear to have 
decreased interest in social interactions. For example, 
a person who is able to speak in full sentences and 
engages in communication but whose to· and·fro 
conversation with others fails, and whose attempts to 
make friends are odd and typically unsuccessful. 
  Inflexibility of behavior causes significant 
interference with functioning in one or more 
contexts. Difficulty switching between activities. 





Similarly,	   clinician	   confirmation	   relies	   on	   a	   diversity	   of	   prompts	   to	   elicit	   a	   child’s	   highest	   capacity	   for	  
social	   communication,	  and	   to	   introduce	  enough	   sensory	  arousal	   to	  elicit	   stereotypic	   responses	   if	   they	  
are	  not	  immediately	  evident.	  Depending	  on	  the	  age	  of	  the	  child	  or	  young	  person	  this	  interaction	  can	  be	  
a	  play	  based	  assessment	  with	   toys	   commonly	  used	  by	  children	  within	   the	   local	   community	  or	  a	  more	  
conversational	   interaction,	  asking	  the	  child	  about	  their	   lives	  at	  home	  and	  school,	   their	   friendships	  and	  
daily	   interactions	   with	   peers.	   Having	   made	   direct	   observations	   of	   the	   child	   and	   gathered	   adequate	  
information	   to	   affirm	   A/B/D,	   the	   clinician	   must	   determine	   whether	   the	   clinical-­‐level	   impairment	   in	  
adaptive	  functioning	  is	  largely	  attributable	  to	  ASD,	  and	  not	  to	  an	  alternate	  psychiatric	  or	  developmental	  
disorder	   (the	   most	   common	   entities	   in	   differential	   diagnosis	   are	   intellectual	   disability,	   language	  
disorder,	  attention	  deficit	  hyperactivity	  disorder	  (ADHD),	  anxiety	  disorders	  and	  psychotic	  disorders).	  For	  
more	   detailed	   information	   on	   assessment	   algorithms,	   we	   refer	   the	   reader	   to	   previously	   published	  














	   	  
Panel C. A case of ASD diagnosed in infancy. 
SS, a boy whose maternal uncle carried a diagnosis of idiopathic intellectual disability, was first evaluated at age 
15 months. His parents were concerned that he would not engage in either symbolic or pretend play. He was not 
capable of (protodeclarative) pointing to share intention and rarely responded to his name being called. He 
seemed preoccupied with things that spin and had a history of peculiar behaviors including examining the 
shadows cast by his fingers for extended periods of time. Despite these concerns, he seemed to recognize what the 
word “no” means, would make eye contact when directly engaged, and enjoyed proximity to his parents. There 
was no history of head trauma or seizures and his hearing was completely intact. 
On clinical exam, SS exhibited marginal eye contact and was preoccupied with objects, including with a ball in 
the room which he began rolling forward, chasing, rolling forward, chasing, etc., and did not respond to the 
examiner’s prompts to join him in the game. He was non-verbal. His parents were counselled on methods to 
engage him in turn-taking reciprocal play, and instructed to return in 3 months to review his progress. At age 18 
months he remained essentially non-verbal, exhibited stereotypic behaviors and a persistent lack of social 
reciprocity, and was given a clinical diagnosis of DSM-IV Pervasive Developmental Disorder (DSM-5 Autism 
Spectrum Disorder). 
By age 7, following years of specialized early childhood and early elementary education, featuring early intensive 
behavioral intervention, speech and language therapy, augmentative communication, occupational therapy, and 
special education with an assigned 1:1 paraprofessional, his receptive language had continued to improve 
although his spontaneous verbal communication remained limited to short phrases and sentences, raising concern 
for the presence of comorbid intellectual disability. He was fairly non-cooperative with intellectual testing and the 
results were not released because it was felt by the assessors that the scores underestimated his true ability. An 
EEG obtained because of intense visual fixation patterns and concern for possible absence epilepsy was non-
epileptiform, but abnormal in that the activity during wakefulness lacked a posterior dominant rhythm. He 
remained in intensive specialized education programs, was well-adapted at home with his family (entirely 
verbally redirectible, non-aggressive, and responsive to his parents’ requests), and although content with isolation, 


















What	  becomes	   immediately	  evident	   in	   the	  diagnostic	  process,	  especially	   for	  milder	  ASD	  syndromes,	   is	  
that	  fulfillment	  of	  the	  A,	  B,	  and	  D	  criteria	  of	  DSM-­‐5	  are,	  by	  definition,	  exquisitely	  sensitive	  to	  the	  notion	  
of	   “clinical	   threshold.”	   	   There	   is	   an	   apparent	   tension	  between	  expert	   clinician	   judgment	   about	  where	  
this	  threshold	  should	  lie	  and	  the	  fundamental	  nature	  of	  A,	  B,	  and	  D	  (their	  respective	  distributions,	  inter-­‐
relationships,	  and	  biological	  causes)	   that	  raises	  continuously-­‐evolving	  questions	  about	  how	  the	  clinical	  
thresholds	   for	  A,	   B,	   and	  D	   should	   be	   established	   for	   the	   purpose	   of	   diagnosis.	   Should	   they	   represent	  
percentile	   cutoffs	   of	   the	   normal	   distribution	   (as	   dominates	   the	   diagnosis	   of	   intellectual	   disability)?	  	  
Should	   a	   patient	   with	   an	   established	   causal	   mutation	   for	   ASD	   whose	   symptoms	   fall	   just	   below	   the	  
current	  clinical	  threshold	  not	  be	  diagnosed?	  	  Should	  absolute	  symptom	  burden	  or	  level	  of	  impairment	  of	  
adaptive	  functioning	  dominate	  parameterization	  of	  the	  clinical	  threshold?	   	   In	  traditional	  ASD	  research,	  
emphasis	   has	   unequivocally	   been	   on	   the	   former.	   If	   sub	   clinical	   ASD	   symptomatology	   exacerbates	  
another	   primary	   diagnosis	   (e.g.	   ADHD	   or	   borderline	   intellectual	   functioning)	   in	   a	   manner	   that	  
substantially	  contributes	  to	  impairment	  in	  adaptive	  functioning,	  should	  a	  diagnosis	  of	  ASD	  be	  invoked?	  	  	  
	   III.	   Evolution	   of	   the	   ‘definition	   of	   disorder’:	   Diagnostic	   boundaries	   and	   their	   effects	   on	  
prevalence.	  
Perhaps	  more	  so	  than	  many	  psychiatric	  disorders,	  the	  evolution	  of	  our	  conception	  of	  what	  autism	  is,	  and	  
how	   its	   diagnostic	   boundaries	   should	   be	   established,	   has	   been	   far	   from	   linear	   since	   the	   initial	   classic	  
Panel D. A case of ASD diagnosed in childhood. 
DP was an 8 year old boy who was described by his mother as “different” from the time he was very young. He 
showed an unusual interest in books about geology and was exceptionally good at puzzles. He was inclined to 
repeat dialogues he had heard on television and passages from books in order to get ideas across. He had poor 
motor skills and at times endangered himself by mindlessly walking onto busy streets.  
During his preschool years, DP rarely socialized with other children, and seemed more disinterested than anxious 
when in their company. In elementary school he was one of the first children in his class to read independently, was 
very proficient in math, but was stigmatized by his behavior. He answered rhetorical questions of his teachers 
aloud without being called upon and blurted out inappropriate comments to peers, which he often found humorous. 
He was disliked by his classmates, regarded as odd by them, and often teased, although he seemed largely 
oblivious to this.  
On clinical examination he exhibited considerable difficulties in maintaining the flow of a conversation with the 
examiner, talked around the subject rather than providing direct responses, and repeatedly resorted to changing the 
conversation to discuss different types of rocks and geologic formations that he perseverated about. His eye contact 
was reasonably good when directly engaged in conversation, but he otherwise appeared aloof and somewhat 
detached. He spoke in a monotone voice, largely devoid of prosodic intonation. He had little insight into the way in 
which he was negatively regarded by his classmates and referred to them as his “friends” despite his mother’s 
assertion that they never ask to play with him or include him in after-school gatherings. 
A structured diagnostic interview regarding his developmental history revealed a level of symptoms that fell below 
the threshold for meeting diagnostic criteria for an autism spectrum disorder, however the burden of symptoms and 
level of impairment evident from the accounts of his parents and teachers, which were confirmed by clinical 
observation and deemed unlikely attributable to an alternate psychiatric diagnosis (e.g. ADHD, intellectual 
disability, anxiety disorder, or language disorder) resulted in a clinical diagnosis of autism spectrum disorder.	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descriptions	  over	  70	  years	  ago	  by	  Leo	  Kanner19	  and	  Hans	  Asperger	  (1944).20	  In	  many	  ways	  these	  pioneer	  
clinicians	   got	   so	   much	   right.	   In	   small	   case	   series	   descriptions	   (11	   children	   in	   Kanner’s	   description	   of	  
‘autistic	  disturbances	  of	  affective	  contact’;	  4	  children	  in	  Asperger’s	  description	  of	  ‘autistic	  psychopathy’)	  
they	   described	   characteristic	   features	   of	   ASD	   that	   are	   instantly	   recognisable	   and	   still	   resonate	   with	  
clinicians	  and	  parents	  today.	  	  
The	   diagnostic	   category	   of	   ‘autistic	   disorder’	   was	   first	   introduced	   into	   the	   psychiatric	   classification	  
system	  in	  Diagnostic	  and	  Statistical	  Manual	  of	  Mental	  Disorders-­‐III.	  The	  description,	  heavily	   influenced	  
by	   Rutter,21	   broadly	  matched	   that	   of	   the	  more	   severe	   cases	   described	   by	   Kanner,19	   characterised	   by	  
delay	   in	   language	   milestones	   and	   poor	   communication	   skills,	   intellectual	   disability	   (previously	   called	  
‘mental	  retardation’),	  social	  aloofness,	  motor	  stereotypes	  and	  intense,	  narrow	  and	  odd	  preoccupations.	  
This	   initial	  description	  still	   survives	   in	   the	  clinical	  vernacular	   today	  when	  clinicians	   refer	   to	  children	  as	  
presenting	  with	  ‘classic’	  or	  ‘Kanner’	  autism.	  From	  this	  point	  on,	  subsequent	  changes	  in	  the	  classification	  
systems	  both	  broadened	  the	  concept	  of	  what	  clinical	  presentations	  should	  be	  included	  in	  what	  we	  now	  
call	  ASD	  –	  along	  with	  this	  the	  number	  of	  individuals	  to	  whom	  the	  diagnosis	  applied	  –	  and	  introduced	  a	  
number	  of	  new	  diagnostic	   labels	  that,	   in	  hindsight	  perhaps	  mistakenly,	  were	  taken	  by	  both	  the	  clinical	  
and	   scientific	   communities	   to	   stand	   for	  meaningful	   subtypes	   of	  ASD.	   First,	  DSM-­‐III-­‐R22	   introduced	   the	  
term	   ‘pervasive	   disorder	   not	   otherwise	   specified’	   (PDD-­‐NOS)	   essentially	   a	   subthreshold	   definition	   of	  
more	  mildly	  affected	  cases.	  Then,	  in	  DSM-­‐IV23	  ‘Asperger’s	  Disorder’	  was	  introduced	  as	  a	  sub-­‐category	  of	  
the	  pervasive	  developmental	  disorders	  that	  recognised	  that	   individuals	  with	  average	  or	  above	  average	  
intellectual	  disability	  and	  intact	  structural	   language	  skills	  could	  also	  show	  the	  clinical	  manifestations	  of	  
ASD.	  
The	   longer	   interval	  before	  the	  next	  revision	  of	  DSM	  in	  2013	  (DSM-­‐5)11	  gave	  more	  time	  for	  clinical	  and	  
basic	  scientific	   research	  to	   inform	  the	  decisions	  that	  were	  made	  by	  the	  workgroup	  than	  had	  been	  the	  
case	   in	   the	   relative	   blitz	   of	   revisions	   between	   1980	   and	   the	   mid-­‐1990s.	   At	   least	   three	   factors	   were	  
influential	  in	  the	  reversion	  to	  a	  single	  disorder	  category	  of	  ‘autism	  spectrum	  disorder’	  (ASD)	  in	  DSM-­‐5.	  
The	  first	  was	  the	  recognition	  that	  ASDs	  were	  aetiologically	  as	  well	  as	  clinically	  heterogeneous,24	  as	  will	  
be	  discussed	  in	  further	  detail	  below.	  The	  second	  factor	  was	  an	  accumulation	  of	  research	  evidence	  that	  
the	  clinical	  subtypes	  described	  in	  DSM-­‐IV	  (autistic	  disorder,	  PDD·∙NOS,	  Asperger’s	  disorder)	  did	  not	  have	  
scientific	  validity	  either	  in	  terms	  of	  different	  neurobiological	  or	  genetic	  aetiology	  or	  of	  truly	  independent	  
cognitive	   associates	   that	   differed	   between	   the	   diagnostic	   subtypes,	   aside	   from	   those	   inherent	   in	   the	  
different	  specific	  diagnostic	  criteria,	  in	  particular	  regarding	  language	  and	  intellectual	  ability.25,26	  This	  may	  
be	  too	  high	  a	  bar	  to	  set	  for	  clinical	  diagnostic	  criteria	  given	  the	  long	  recognised	  fact	  that	  clinical	  utility	  
and	   (natural)	   validity	   are	   not	   the	   same	   thing.27	   However,	   it	   became	   increasingly	   apparent	   that	   the	  
diagnostic	   subtypes	   lacked	   clinical	   validity.	   Only	   a	   few	   years	   after	   the	   publication	   of	   DSM-­‐IV	   that	  
introduced	  Asperger’s	  Disorder	  into	  the	  classification	  system,	  Miller	  and	  Ozonoff28	  reviewed	  the	  original	  
case	  descriptions	  in	  the	  1944	  Hans	  Asperger	  paper	  and	  concluded	  that	  all	  cases	  would	  have	  met	  DSM-­‐IV	  
criteria	  for	  Autistic	  Disorder.	  A	  recent	  seminal	  study	  that	  is	  likely	  to	  have	  strongly	  influenced	  the	  DSM-­‐5	  
reversion	  to	  a	  single	  ASD	  category	  was	  that	  even	  amongst	  expert	   research	  groups	  the	  use	  of	   the	  sub-­‐




The	  final	  change	  in	  DSM-­‐5	  was	  the	  introduction	  of	  ‘clinical	  specifiers’	  to	  be	  noted	  alongside	  the	  
diagnosis,	  including	  the	  presence/absence	  of	  language	  impairment,	  intellectual	  impairment,	  known	  
medical,	  genetic	  condition	  or	  environmental	  factor,	  another	  neurodevelopmental,	  mental,	  or	  
behavioural	  disorder,	  catatonia	  and	  onset	  (e.g.	  with	  regression).	  The	  degree	  to	  which	  the	  simplified	  
nosology	  and	  structure	  of	  DSM-­‐5	  –	  and	  the	  clinical	  and	  research	  utility	  of	  the	  specifiers	  –	  is	  a	  better	  
description	  of	  nature	  will	  only	  be	  known	  when	  a	  body	  of	  empirical	  work	  using	  the	  system	  has	  
accumulated.	  One	  concern	  is	  that	  DSM-­‐5	  has	  introduced	  a	  diagnostic	  constriction	  with	  epidemiological	  
evidence	  that	  up	  to	  20%	  of	  individuals	  who	  met	  criteria	  for	  one	  of	  the	  pervasive	  developmental	  
disorders	  under	  DSM-­‐IV	  not	  meeting	  DSM-­‐5	  criteria,	  in	  particular	  those	  without	  intellectual	  disability	  
(Maenner	  et	  al.,	  2014,	  JAMA	  Psychiatry,	  71,	  292-­‐300).	  DSM-­‐5	  also	  introduced	  a	  new	  diagnostic	  category	  
Social	  (Pragmatic)	  Communication	  Disorder	  characterized	  by	  persistent	  difficulties	  using	  verbal	  and	  
nonverbal	  communication	  for	  social	  purposes,	  in	  the	  absence	  of	  restricted	  and	  repetitive	  interests	  and	  
behaviors	  (and	  in	  the	  absence	  of	  ASD),	  although	  its	  clinical	  utility,	  evidence-­‐base	  and	  relation	  to	  ASD	  are	  
currently	  unknown	  (Norbury,	  2014,	  JCPP,	  55,	  204-­‐216).	  It	  remains	  to	  be	  seen	  how	  services,	  insurers	  and	  
commissioners	  respond	  to	  these	  radical	  changes	  to	  the	  diagnostic	  system	  and	  also	  whether	  family	  
members	  and	  individuals	  with	  ASD	  welcome	  the	  changes.	  	  We	  note	  also	  that	  there	  are	  as	  yet	  unresolved	  
questions	  about	  whether	  diagnoses	  like	  Social	  Communication	  Disorder	  (in	  which	  SC	  and	  RRB	  deficits	  
are	  dissociated)	  or	  Asperger	  Disorder	  (eliminated	  from	  DSM-­‐5,	  in	  which	  SC	  and	  structural	  language	  
impairments	  are	  dissociated)	  represent	  biologically-­‐tractable	  subtypes	  of	  Autism	  Spectrum	  Disorders	  
(Lai	  et	  al,	  Brain	  2013),	  whether	  or	  not	  they	  fall	  into	  phenotypic	  or	  genetic	  continua	  with	  the	  remainder	  
of	  the	  spectrum.	  
Finally,	   and	   at	   first	   sight	   somewhat	   contradictorily,	   alongside	   the	   recognition	   that	   there	   is	   wide	  
heterogeneity	  and	  variability	  in	  presentations	  –	  across	  individuals	  who	  meet	  diagnostic	  criteria	  for	  ASD,	  
among	   their	   close	   relatives,	   and	   to	   some	  degree	  within	   individuals	  over	   the	   life	   course	  –	   there	  was	  a	  
recognition	  that	  the	  core	  features	  were	  better	  understood	  as	  a	  spectrum	  of	  presentations.	  The	  seminal	  
work	  of	  Lorna	  Wing,30	  Gillberg,31	  Pickles	  et	  al.32	  and	  Piven	  and	  colleagues33	  in	  recognising	  this	  stimulated	  
attempts	   to	   standardize	   the	   ascertainment	   of	   autistic	   symptoms	   for	   both	   affected	   and	   unaffected	  
individuals	  in	  ASD-­‐affected	  families.	  	  
Standardized	  measures	  
A	   wide	   number	   of	   screening	   and	   diagnostic	   instruments	   have	   been	   developed	   over	   the	   past	   two	  
decades	  (for	  a	  review	  see:	  Charman	  &	  Gotham,	  2013).17	  However,	  a	  long	  list	  of	  potential	  tools	  to	  choose	  
from	   is	   not	   necessarily	   a	   good	   thing	   for	   either	   the	   clinical	   or	   research	   fields,	   in	   particular	   when	   the	  
instrument	   properties	   of	   many	   of	   these	   tools	   have	   not	   been	   extensively-­‐studied	   or	   well-­‐established.	  
However,	  a	  number	  of	  instruments	  have	  been	  widely	  validated	  and	  are	  increasingly	  used	  in	  research	  and	  
clinical	   practice	   in	  many	   countries.	   They	   range	   from	   checklist	   questionnaires	   for	   screening	   and	   rapid	  
ascertainment	  of	  symptom	  severity	  to	  structured	  diagnostic	  instruments	  including	  the	  Autism	  Diagnostic	  
Interview	   Revised	   (ADI·∙R),34	   the	   Developmental,	   Dimensional,	   and	   Diagnostic	   Interview	   (3Di)35	   and	  
observational	  measures	   such	   as	   the	  Autism	  Diagnostic	  Observation	   Schedule	   –	   2nd	   Edition	   (ADOS·∙2).29	  
While	  there	  is,	  as	  expected,	  overlap	  in	  the	  concepts	  and	  the	  content	  of	  ASD	  rating	  scales	  and	  diagnostic	  
instruments,	  they	  differ	  in	  the	  aspect	  of	  the	  diagnostic	  process	  to	  which	  they	  apply	  (i.e.	  developmental	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history	  versus	  current	  symptom	  ascertainment	  versus	  clinician	  confirmation),	  the	  populations	  for	  whom	  
they	  are	  standardized,	  the	  degree	  to	  which	  they	  are	  sensitive	  measures	  of	  sub-­‐clinical	  variation	  in	  ASD	  
traits,	  level	  of	  requirement	  for	  trained	  raters,	  length,	  cost,	  and	  feasibility	  in	  clinical	  settings.	  Amongst	  the	  
most	   notable	   limitations	   is	   the	   degree	   to	   which	   the	   accuracy	   of	   many	   screening	   and	   diagnostic	  
instruments	   have	   been	   validated	   with	   individuals	   with	   ASD	   with	   intellectual	   disability.	   There	   is	   also	  
recognition	   that	   few	   of	   the	   tools	   have	   been	   validated	   in	   non-­‐Western	   cultures	   and	   low-­‐	   and	  middle-­‐
income	  countries	  (in	  part	  the	  same	  could	  be	  said	  about	  the	  diagnostic	  construct	  –	  although	  this	  was	  an	  
issue	  that	  Lotter	  studied	  in	  the	  1970s),	  although	  such	  work	  has	  begun.	  
IV. Quantitative	  approaches	  to	  the	  ascertainment	  of	  symptom	  burden	  
When	  standardized	  methods	  for	  quantitative	  assessment	  of	  ASD	  symptoms	  and	  traits	  have	  been	  applied	  
to	   the	   general	   population,	   the	   unequivocal	   result	   from	   a	   host	   of	   studies,	   implementing	   numerous	  
measurement	   instruments,	   is	   that	   the	   characteristic	   traits	   and	   features	   that	   characterize	   autism	   are	  
continuously—not	   bimodally—distributed	   in	   nature.	   3,5,35,36	   This	   observation	   implies	   that	   there	   is	   an	  
arbitrary	   nature	   to	   diagnostic	   cut-­‐offs	   in	   ASD,	   and	   invokes	  methods	   that	   have	   been	   applied	   to	   other	  
quantitative	  human	  traits—such	  as	  height,	  weight,	  intelligence,	  blood	  pressure—to	  derive	  standardized,	  
percentile-­‐based	  guidelines	  for	  clinical	  diagnosis.	  Remarkably,	  the	  characteristic	  traits	  and	  symptoms	  of	  
the	   autistic	   syndrome	   (deficits	   in	   reciprocal	   social	   behavior,	   impairment	   in	   social	   communication,	  
repetitive	   behavior,	   and	   restriction	   in	   range	   of	   interests)	   are	   as	  highly	   inter-­‐correlated	   in	   the	   general	  
population	  as	  they	  are	  (by	  definition)	  in	  individuals	  with	  clinical	  ASD	  syndromes.	  Such	  homologous	  factor	  
structures	  substantiate	  the	  use	  of	  unitary	  scores	  (akin	  to	  IQ	  for	  intelligence)	  as	  valid	  indices	  of	  symptom	  
burden	  in	  both	  clinical	  and	  non-­‐clinical	  populations,37	  even	  though	  the	  overlap	  in	  biological	  causation	  of	  
the	  respective	  symptom	  domains	  is	  not	  fully	  understood.38	  As	  of	  this	  writing	  it	  remains	  unclear	  whether	  
sub-­‐profiles	   of	   the	   autistic	   syndrome,	   featuring	   more	   or	   less	   involvement	   of	   one	   or	   another	   of	   the	  
respective	  symptom	  domains,	  will	  reliably	  map	  to	  independent	  sets	  of	  biological	  causes.39	  
Furthermore,	   when	   standardized	   quantitative	   methods	   are	   implemented	   in	   the	   study	   of	   families	  
affected	  by	  ASD,	  sub	  clinical	  autistic	  symptoms	  and	  traits	  are	  observed	  among	  first	  degree	  relatives	  with	  
a	  frequency	  an	  order	  of	  magnitude	  higher	  than	  observed	  in	  the	  general	  population.40,41	  Recently,	  in	  very	  
large	  genetic-­‐epidemiologic	  studies	  it	  has	  been	  confirmed	  that	  the	  genetic	  susceptibilities	  to	  these	  sub	  
clinical	   syndromes	   exhibit	   near-­‐complete	   overlap	   with	   genetic	   underpinnings	   of	   the	   clinical-­‐level	  
syndromes,42	   strongly	   suggesting	   that	   the	   continuous	   distributions	   observed	   in	   nature	   relate	   to	  
quantitative	   accumulation	   of	   causal	   liability	   (see	   Constantino,	   20113	   for	   a	   more	   detailed	   review	   of	  
discrete	  sub	  populations	  that	  partially	  contribute	  to	  the	  continuum	  observed	  in	  nature).	  Thus,	  although	  
the	  diagnostic	  criteria	  for	  ASD	  do	  not	  yet	  consider	  percentile	  rank	  in	  the	  population	  distribution	  (as	  do	  
diagnostic	   criteria	   for	   anorexia	   nervosa,	   hypertension,	   intellectual	   disability,	   and	   short	   stature),	   an	  
increasingly-­‐compelling	  case	  can	  be	  made	  for	  parameterizing	  diagnostic	  thresholds	  in	  this	  manner.43	  An	  
in	  depth,	   two-­‐stage	  population	   study	  of	  autism	  prevalence	   revealed	   identified	  2.5%	  of	   the	  population	  
affected,44	   encroaching	   the	   proportion	   that	   defines	   clinical	   thresholds	   for	   other	   human	   quantitative	  
traits	  (e.g.,	  height	  and	  short	  stature).	  A	  recent	  systematic	  review	  of	  studies	  using	  a	  self-­‐report	  measure	  
of	  autism	  traits	  (Autism	  Quotient;	  AQ)	  has	  demonstrated	  that	  both	  males	  and	  females	  show	  a	  close-­‐to-­‐
normal	   distribution	   but	   a	   highly	   significant	   shift	   between	   the	   sexes	   with	   males	   scoring	   higher	   than	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females	   (Ruzich	   et	   al.,	   2015,	  Molecular	   Autism,	   6:2).	   Failure	   to	   incorporate	   sex-­‐specific	   norms	   in	   the	  
diagnostic	   process	   has	   contributed	   to	   significant	   differences	   in	   rates	   of	   community	   diagnosis	   for	   girls	  
versus	   boys	  manifesting	   precisely	   the	   same	   level	   of	   quantitative	   symptom	   burden,	   3,45,46	   and	   there	   is	  
evidence	   that	   female	   sex	   can	   very	   often	  moderate	   the	   phenotypic	   expression	   of	   inherited	   liability	   to	  
ASD.	  87,89	  	  
Moreover,	   in	   the	   same	  way	   that	   height	   influences	  weight,	   the	   neurodevelopmental	   characteristics	   of	  
intelligence,	   attention,	   structural	   language	   capacity,	   emotion	   regulation	   and	   executive	   function	   can	  
influence	   social	   communication,	   such	   that	   specification	   of	   the	   role	   of	   autistic	   symptomatology	   in	   an	  
individual	   patient	   will	   ultimately	   require	   established	  maps	   of	   the	   expectable	   relations	   between	   the	  
variables	  (analogous	  to	  the	  height	  versus	  weight	  norms	  for	  males	  and	  females	  used	  in	  pediatric	  practice)	  
to	  accurately	  ascertain	  the	  relative	  contribution	  of	  ASD	  symptomatology	  to	  a	  given	  neurodevelopmental	  
syndrome.47	  This	  is	  becoming	  especially	  relevant	  now	  that	  biological	  influence	  on	  each	  (separable)	  axis	  
of	  human	  development	  is	  becoming	  better	  understood,	  and	  that	  it	  is	  common	  for	  even	  rare	  monogenic	  
syndromes	  to	  exert	  adverse	  influences	  on	  multiple	  domains	  of	  development	  (e.g.,	  effects	  of	  16p11.2	  on	  
intelligence,	   social	   responsiveness,	   and	   weight10),	   each	   influenced	   by	   the	  mutation	   in	   a	  manner	   that	  
represents	   a	   predictable	   shift-­‐from-­‐expected	   against	   a	   (bi	   parental)	   genetic	   and	   environmental	  
background	  for	  that	  trait.	  	  In	  this	  way	  rare	  syndromes	  can	  be	  more	  deeply	  understood,	  i.e.	  not	  simply	  by	  
the	  variable	  and	  idiosyncratic	  array	  of	  deficits	  with	  which	  they	  are	  associated,	  but	  by	  how	  they	  influence	  
such	  traits	  in	  the	  setting	  of	  the	  specific	  genetic	  and	  environmental	  background	  of	  an	  individual.	  
	  
V. Causation,	  and	  an	  Impending	  Revolution	  in	  ASD	  Diagnosis	  
	  
The	  past	  decade	  has	  witnessed	  an	  explosion	  in	  scientific	  discovery	  of	  the	  causes	  of	  autism.	  Although	  to	  
date	   there	   remains	   neither	   a	   laboratory	   test	   nor	   a	   neural	   signature	   that	   can	   reliably	   establish	   the	  
presence	   of	   a	   non-­‐syndromic	   ASD,	   a	   rapidly-­‐increasing	   proportion	   of	   all	   cases—encroaching	   the	  
majority—are	  resolvable	  to	  the	   influence	  of	  deleterious	  molecular	  genetic	  variants	  or	  combinations	  of	  
variants,	  and	  it	   is	  expected	  that	  this	  will	  play	  a	  major	  role	  in	  revolutionizing	  diagnosis.	  Twin	  and	  family	  
studies	   involving	   tens	   of	   thousands	   of	   individuals	   in	   ASD-­‐affected	   families	   have	   overwhelmingly	  
established	   the	   role	   of	   genetic	   factors	   in	   accounting	   for	   the	   majority	   of	   causal	   influence	   on	   autistic	  
syndromes.24,48,49	   Accumulated	   results	   of	   molecular	   genetic	   studies	   published	   to	   date	   have	   made	  
enormous	  progress	  in	  accounting	  for	  this	  inherited	  variance,	  and	  have	  revealed	  the	  following:	  	  
	  
1) Causal	  heterogeneity:	  A	  diverse	  array	  of	  rare	  (less	  than	  1%	  of	  all	  cases,	  usually	  less	  than	  0.1%	  of	  all	  
cases),	   highly-­‐penetrant	   mutations	   –	   some	   de	   novo,	   some	   recessive	   inherited,	   the	   vast	   majority	  
involving	  autosomal	  loci—account	  for	  up	  to	  40	  per	  cent	  of	  autistic	  syndromes	  (see	  6,50);	  	  
2) Pleiotropic	   effects	   of	   rare	   causal	   variants:	   Many	   of	   the	   rare	   variants	   that	   have	   been	   repeatedly	  
associated	  with	  ASD	  have	  also	  been	  strongly	   implicated	   in	  the	  causation	  of	  other	  neuropsychiatric	  
syndromes,	  including	  epilepsy,	  ADHD,	  schizophrenia,	  and	  intellectual	  disability.8	  	  Furthermore,	  in	  the	  
presence	  of	  some	  highly-­‐penetrant	  disease-­‐causing	  mutations	  (e.g.	  16p11.2	  deletion	  syndrome),	  the	  
expression	   of	   ASD	   symptoms—ascertained	   using	   standardized	   methods—can	   be	   highly	   variable,	  
influenced	  in	  large	  measure	  by	  family	  genetic	  background.10	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3) Quantitative	  genetic	  risk:	  	  common	  allelic	  variations,	  each	  presumably	  individually-­‐preserved	  in	  the	  
human	   population	   on	   the	   basis	   of	   adaptive	   value	   (in	   an	   evolutionary	   sense)—and	   none	   of	  which	  
singly	  can	  account	  for	  more	  than	  a	  tiny	  elevation	  in	  risk	  for	  ASD	  (odds	  ratio	  between	  1·0	  and	  1·2)—
are	   responsible	   for	   the	  majority	  of	  genetic	   risk	   for	  ASD	  on	   the	  basis	  of	   cumulative	  polygenic	   risk.4	  
Furthermore,	  specific	  sets	  of	  common	  and	  rare	  inherited	  allelic	  variations	  have	  been	  associated	  with	  
a	  range	  of	  neuropsychiatric	  conditions	   (including	  both	  childhood-­‐onset	  and	  adult-­‐onset	  disorders),	  
and	   further	   resolution	   of	   these	   relationships	   will	   contribute	   to	   moving	   beyond	   descriptive	  
syndromes	  in	  psychiatry,	  and	  towards	  a	  nosology	  informed	  by	  causation.8,50,51	  
	  
These	  findings	  have	  collectively	  suggested	  that	  the	  continuum	  of	  ASD	  traits	  observed	  in	  the	  population	  
reflects	   the	   human	   distribution	   of	   polygenic	   risk,	   superimposed	   by	   clusters	   of	   cases	   attributable	   to	   a	  
massively-­‐overlapping	   array	   of	   rare,	   discrete	   molecular	   genetic	   variants	   of	   moderate·∙	   to	   high-­‐level	  
penetrance.	   In	   turn,	   the	   phenotypic	   expression	   of	   these	   genetic	   influences	   varies	   on	   the	   basis	   of	   the	  
manner	  in	  which	  any	  discrete	  genetic	  cause	  interacts	  with	  other	  attributes	  of	  the	  genetic	  background,10	  
the	   intrauterine	   environment,	   	   and	   early	   experience43	   of	   the	   individual	   (including,	   for	   example,	  
infectious	   diseases,	   serious	   medical	   complications	   during	   the	   neonatal	   period,	   or	   as	   yet	   poorly	  
understood	   effects	   of	   variation	   in	   the	   human	   microbiome).	   This	   reinforces	   an	   orientation	   to	   a	  
personalized	   medicine	   approach	   to	   both	   diagnosis	   and	   treatment	   as	   is	   now	   implemented	   for	   many	  
complex	  diseases,	  most	  notably	  in	  the	  field	  of	  oncology.	  	  
	  
Resolution	   of	   many	   autistic	   syndromes	   with	   respect	   to	   the	   relative	   contribution	   of	   specific	   genetic	  
variants	   also	   continues	   to	   illuminate	   understanding	   of	   the	   biology	   of	   autism	   “comorbidities”	   such	   as	  
ADHD,	   motor	   coordination	   impairment,53·∙55	   epilepsy,	   intellectual	   disability,	   anxiety,	   and	   the	  
psychopathologies.	  Although	  none	  of	  these	  symptom	  clusters	  are	  specific	  to	  ASD,	  some	  mutations	  (e.g.	  
Fragile	   X	   Syndrome,	   Neurofibromatosis	   Type	   1,	   Tuberous	   Sclerosis,	   and	   a	   host	   of	   newly-­‐discovered	  
variants)	   have	   been	   associated	   with	   predictable	   profiles	   of	   comorbidity	   (whenever	   ASD	   arises)	   and	  
therefore	   blur	   the	   distinction	   between	   “core	   symptoms”	   and	   “associated	   symptoms,”	   at	   least	   in	   the	  
setting	   of	   these	   monogenic	   syndromes.	   In	   other	   pathways	   to	   ASD,	   associated	   symptoms	   are	   better	  
predicted	   by	   family	   genetic	   background,	   appear	   exacerbated	   by	   the	   presence	   of	   ASD,	   and	   are	   not	  
themselves	  predictive	  of	  a	  specific	  ASD	  susceptibility.39	  
	  
In	   summary,	   advances	   in	   understanding	   the	   causes	   of	   autism—its	   genetic	   and	  population	   structure—
suggest	  that	  diagnosis	  will	  ultimately	  benefit	  from	  further	  movement	  toward	  standardized	  quantitative	  
characterization	   of	   the	   defining	   features	   of	   ASD,	   conducted	   simultaneously	  with	   (and	   controlling	   for)	  
multi-­‐axial	  characterization	  of	  those	  aspects	  of	  human	  development	  that	  influence	  the	  manifestation	  of	  
autistic	  symptoms	  and	  impairments,	  and	  from	  the	  inclusion	  of	  genotype	  in	  taxonomic	  classification.	  For	  
some	  putative	  causes	  of	  ASD,	  we	  are	  still	  at	  an	  early	  stage	  in	  the	  conversion	  from	  statistical	  association	  
in	   large	   genetic	   studies	   to	   knowledge	   of	   the	   specific	   impact	   of	   a	   deleterious	   variant	   in	   an	   individual	  
patient—recently	   Yuen	   et	   al.,7	   showed	   that	   among	   siblings	   concordantly-­‐affected	   by	   ASD,	   when	   one	  
carries	  what	  would	  be	  presumed	  to	  be	  a	  highly-­‐deleterious	  variant,	  the	  other	  affected	  sibling	  may	  not	  
share	  that	  variant,	  such	  that	  familial	   liability	   is	  driven	  more	  by	  background	  genetic	  factors	  upon	  which	  
rare	  variants	  no-­‐shared	  between	  family	  members	  are	  responsible	  for	  crossing	  over	  the	  “tipping	  point”	  of	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clinical-­‐level	   affectation.	   As	   the	   cost	   of	   genotyping	   continues	   to	   fall,	   as	   false	   discovery	   rates	   are	  
minimized,52	  as	  increasing	  proportions	  of	  patients’	  conditions	  are	  traced	  to	  specific	  genetic	  variants,	  and	  
the	  sample	  sizes	  of	  large	  genetic	  registries	  continue	  to	  grow,	  the	  relative	  impact	  of	  causal	  and	  protective	  
variants	   in	  an	   individual	  patient	  will	  become	   increasingly	  specified.	  Even	  as	   this	   is	  evolving,	  calibrating	  
clinical	   practice	   in	   a	   manner	   that	   raises	   awareness	   of	   the	   impact	   and	   relevance	   of	   quantitative	  
phenotypes,	  of	  multiplier-­‐effects	  of	   comorbid	  developmental	   liabilities,	   and	  of	   the	  opportunity	   to	   sub	  
group	   patients	   on	   the	   basis	   of	   deleterious	   variants	   stands	   to	   accelerate	   the	   discovery	   process.	   As	  
personalized	  therapies	  begin	  to	  demonstrate	  differential	   impact	  as	  a	  function	  of	  specific	  genetic	  origin	  
(see	  56·∙58)	  the	  benefits	  of	  an	  updated	  diagnostic	  nosology	  will	  translate	  further	  into	  the	  delivery	  of	  more	  
tailored	  and	  sophisticated	  care	  for	  patients,	   in	  addition	  to	   its	  own	  positive	   impact	  on	  the	  pace	  of	  new	  
discovery.	  	  
	  
VI. Advancing	  the	  Frontier	  of	  Early	  Diagnosis	  
	  
Another	  traditional	  diagnostic	  boundary	  that	   is	  being	  broached	  by	  advances	   in	  science	   is	  the	  timing	  of	  
diagnosis.	   It	   has	   long	   been	   recognised	   that	   ASDs	   have	   an	   early	   onset,	   and	   a	   primary	   motivation	   for	  
seeking	   to	   lower	   the	   age	   of	   diagnosis	   of	   ASD	   is	   to	   enable	   evidence-­‐based	   interventions	   to	   be	   put	   in	  
place.59,60	   Several	   converging	   lines	   of	   evidence	   support	   this	   view,	   including	   increased	   neural	   plasticity	  
early	   in	   life,	   evidence	   from	  prospective	   infant	   sibling	   studies	   that	   atypical	   neurodevelopment	  may	   be	  
present	   even	   in	   the	   first	   year	   of	   life61	   and	   preliminary	   evidence	   that	   some	   of	   these	   atypical	  
developmental	  processes	  may	  be	  amenable	  to	  intervention	  from	  as	  young	  as	  10	  months	  of	  age.62,63	  Over	  
the	   past	   20	   years	   an	   increasing	   number	   of	   studies	   have	   reported	   on	   outcomes	   of	   children	  with	   ASD	  
diagnosed	  at	  a	  very	  young	  age	  either	  from	  clinical	  referrals	  of	  young	  children	  or	  from	  children	  identified	  
as	   at	   risk	   on	   the	   basis	   screening	   or	   familial	   risk.	   After	   initial	   studies	   by	   Lord64	   and	   Cox	   et	   al.,65	  more	  
recent	  studies	  have	  followed	  children	  from	  2	  years	  of	  age	  to	  766	  and	  9	  years	  of	  age67,	  68.	  In	  short,	  these	  
studies	   find	   that	   diagnosis	   from	   as	   young	   as	   2	   years	   of	   age	   is	   relatively	   stable	   and	   the	   judgement	   of	  
experienced	  clinicians	  is	  more	  reliable	  than	  that	  of	  existing	  diagnostic	  instruments.	  Notwithstanding	  this,	  
there	  can	  be	  particular	  difficulties	  when	  considering	  a	  diagnosis	  of	  ASD	   in	  very	  young	  children	  ranging	  
from	   the	   overlap	   in	   presentation,	   and	   hence	   differential	   diagnosis,	   with	   children	   with	   intellectual	  
disability	  or	   language	  delay,	   to	   the	  difficulty	   in	   judging	   the	  extent	   to	  which	   there	   is	   an	   impairment	   in	  
adaptive	  and	  wider	  social	  functioning,	  for	  example	  when	  a	  young	  child	  is	  mostly	  cared	  for	  by	  parents	  or	  
familiar	   caregivers	   and	   has	   little	   opportunity	   for	   broader	   social	   interaction	   with	   peers.	   In	   such	  
circumstances	  the	  notion	  of	  a	  ‘working	  diagnosis’	  with	  ongoing	  surveillance,	  monitoring	  and	  review	  over	  
the	   course	   of	   sequential	   assessments	   can	   be	   valuable	   and	   help	   both	   clinicians	   and	   parents	   to	   better	  
understand	   and	   recognise	   the	   pattern	   of	   development	   that	   will	   clarify	   the	   diagnosis	   one	  way	   or	   the	  
other.69	  
Increasingly	   sophisticated	   approaches	   have	   been	   adopted	   to	   examine	   trajectories	   of	   ASD	   symptoms	  
over	   time.	   These	   studies	   have	   demonstrated	   that	   in	  most	   individuals	   symptom	   profiles	   are	   relatively	  
stable	   from	  age	  2	  years	   to	  adolescence,	  although	  some	  20%	  of	  children	  who	  are	  ultimately	  diagnosed	  
with	  ASD	  experience	  marked	  regressions	  following	  apparently	  healthy	  developmental	  progress	  over	  the	  
first	   two	   years	   of	   life.	   	   Moreover,	   around	   10%	   of	   individuals	   show	   improving	   trajectories,12	   dubbed	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‘bloomers’	   by	   Fountain	   et	   al.70	   Confirming	   the	   broad	   independence	   between	   symptom	   severity	   and	  
adaptive	  impairment,	  a	  recent	  study	  has	  shown	  that	  distinct	  ‘trajectories	  groupings’	  in	  these	  domain	  are	  
largely	   non-­‐overlapping	   during	   the	   preschool	   period.71	   Similar	   analyses	   have	   been	   conducted	   with	  
infants	  at	  familial	  risk	  of	  ASD	  on	  the	  basis	  of	  having	  an	  older	  sibling	  with	  ASD.	  Using	  this	  at-­‐risk	  design	  it	  
is	  possible	  to	  track	  from	  as	  young	  as	  6	  months	  of	  age	  the	  trajectory	  of	  the	  ~20%	  of	  at-­‐risk	  siblings	  who	  
go	  on	  to	  have	  ASD	  at	  36	  months	  of	  age.72	  Landa	  and	  colleagues73,74	  and	  Ozonoff	  and	  colleagues75,76	  have	  
shown	   that	  whilst	   the	   different	   outcome	   groups	   look	   similar	   at	   6	  months	   of	   age,	   soon	   after	   the	   first	  
birthday	  the	  trajectories	  of	  those	  who	  go	  on	  to	  receive	  a	  diagnosis	  of	  ASD	  begin	  to	  diverge,	  with	  subtle	  	  
developmental	  slowing	  across	  a	  range	  of	  domains	  including	  motor,	  language	  and	  social	  communication	  
abilities	   (as	   shown	   in	   Figure	   1).	   The	   task	   ahead	   is	   to	   understand	   the	   constitutional	   (e.g.	   variability	   in	  
genetic	  and	  brain	  structure	  and	  function)	  and	  environmental	  (e.g.	  demographic,	  specific	   interventions)	  
factors	  that	  influence	  such	  trajectories.	  Until	  recently,	  the	  evidence-­‐base	  for	  psychological	  interventions	  
with	  young	  children	  with	  ASD	  was	  poor	  both	  in	  terms	  of	  quality	  and	  quantity.	  However,	  a	  ‘new-­‐wave’	  of	  
better-­‐designed	   randomized	   controlled	   trials	   demonstrate	   increasing	   evidence	   for	   interventions	   that	  
employ	  behavioral	  and	  developmental	  approaches.13,77,78	  	  	  
Figure	  1.	  Reprinted	  from	  J Am Acad Child Adolesc Psychiatry. 2010 Mar; 49(3): 256–66	  
Efforts	   to	   advance	   earlier	  
diagnosis	   have	   also	  
revealed	   neurocognitive	  
signatures	   of	   early	   ASD	  
risk	   that	  may	   yield	   a	   first	  
generation	   of	   diagnostic	  
biomarkers	   that	   are	  
shared	   by	   many	   or	   most	  
autistic	   syndromes.	  
Studies	   of	   infants	   at	  
familial	   risk	   of	   ASD	   have	  
utilized	   novel	  
technologies,	   including	  
eye	   tracking	   and	  
electroencephalogram	  
(EEG)/event	   related	  
potential	   (ERP)	   methods,	  
to	   study	   the	   infant	  
neurocognitive	   predictors	  
of	  later	  ASD	  diagnosis.61	  A	  
number	   of	   neurocognitive	   biomarkers	   have	   been	   identified	   in	   the	   first	   year	   of	   life.	   These	   include	  
differences	   in	   social	   response,	   such	   as	   a	   decline	   in	   eye	   fixation	  when	   viewing	   faces	   between	   2	   and	   6	  
months,79	   reduced	   social	   orienting80	   and	   a	   reduced	   neural	   response	   to	   dynamic	   gaze	   shifts	   from	   6	  
months	  of	  age.81	  However,	  differences	  in	  non-­‐social	  neurocognitive	  processes	  have	  also	  been	  associated	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with	   later	   ASD,	   including	   shorter	   fixation	   duration	   at	   7	   months	   of	   age82	   and	   a	   decline	   in	   attentional	  
disengagement	  ability	  between	  7	  and	  14	  months.83	  Whilst	  no	  global	   theoretical	   account	  has	  achieved	  
widespread	   acceptance	   a	   number	   of	  models	   of	   emergent	   neurodevelopmental	   atypicality	   have	   been	  
proposed.84,85	  The	  clinical	  field	  awaits	  the	  outcome	  of	  the	  translational	  work	  that	  has	  now	  begun	  before	  
such	  technologies	  can	  be	  used	  in	  a	  reliable	  way	  to	  augment	  behavioural	  assessment	  of	  individual	  infants	  
and	   toddlers	   to	   aid	   early	   diagnosis	   in	   the	   future.	   However,	   caution	   is	   required	   as	   it	   remains	   unclear	  
whether	   the	   findings	   from	   familial	   high-­‐risk	   infants	   will	   generalize	   to	   the	   broader	   population	   of	  
individuals	  with	  ASD,	  as	  well	  as	  the	  extent	  to	  which	  the	  findings	  are	  specific	  to	  ASD	  as	  opposed	  to	  other	  
neurodevelopmental	   disorder	   such	   as	  ADHD	  and	   language	  delay	   (Johnson	  et	   al.,	   2015,	   JCPP,	   56,	   228-­‐
247).	  
Even	   when	   they	   are	   ready	   for	   implementation,	   it	   will	   be	   important	   for	   clinicians	   to	   remain	  
consummately	  mindful	  of	   the	   limitations	  of	  prediction	   in	   individual	  patients,	   and	   that	  diagnosis	   is	  not	  
equivalent	  to	  prognosis.	  Although	  autistic	  severity	  is	  remarkably	  stable	  over	  the	  course	  of	  life	  in	  a	  group-­‐
statistical	   sense,12	   slow,	   steady	   recoveries	   occur	   in	   isolated	   cases,	   steady	   improvement	   in	   adaptive	  
functioning	  is	  achievable	  for	  most	  patients,	  and	  hope	  is	  a	  critical	  ingredient	  for	  families	  to	  continuously	  
(throughout	   life)	   marshal	   the	   resources	   and	   supports	   necessary	   to	   optimize	   the	   adaptation	   and	  
development	  of	  affected	   individuals.	   In	  this	  sense,	  over-­‐prognostication	  carries	  with	   it	  the	  potential	  to	  
do	  real	  harm,	  and	  predictions	  about	  any	  child’s	   life	  prospects	  are	  best	  kept	  open,	  with	  an	  appropriate	  
emphasis	  on	  what	  is	  possible,	  and	  honest	  recognition	  of	  the	  limits	  of	  what	  is	  known.	  It	  is	  important	  that	  
children	  with	  ASD	  be	  viewed	  by	  clinicians,	  families,	  and	  themselves	  as	  children	   first	  and	  having	  autism	  
second	  (not	  the	  other	  way	  around),	  and	  for	  affected	  individuals	  to	  be	  unequivocally	  respected	  for	  their	  
own	   effort	   to	   overcome	  whatever	   threatens	   to	   limit	   their	   freedoms	   or	   relationships	   or	   expression	   of	  
themselves,	  a	  striving	  that	  is	  shared	  by	  all	  people,	  with	  and	  without	  diagnosed	  disabilities.	  	  
VII. Factors	  associated	  with	  under-­‐diagnosis	  
	  
Over	   the	  past	  decade	   it	   has	  become	  clear	   that	   a	  number	  of	   social	   and	   cultural	   factors	   are	   associated	  
with	  the	  likelihood	  of	  individuals	  receiving	  a	  community	  clinical	  diagnosis	  of	  ASD.86	  Even	  when	  displaying	  
the	  same	  level	  of	  ASD	  symptoms,	  girls	  are	  less	  likely	  to	  be	  diagnosed	  than	  boys	  and	  those	  that	  receive	  a	  
diagnosis	  show	  more	  intellectual	  and	  behavioural	  impairment.45	  It	  remains	  unclear	  the	  extent	  to	  which	  
this	   is	   explained	   by	   the	   thresholds	   on	   current	   screening	   and	   diagnostic	   instruments	   (or	   clinical	  
judgement)	  working	   differently	   for	  males	   and	   females	   (and	   thus	   require	   sex-­‐specific	   recalibration)	   or	  
whether	  girls	  are	  typically	  protected	  against	  the	  expression	  of	  inherited	  ASD	  susceptibility	  in	  a	  manner	  
that	   would	   contribute	   to	   the	   universally-­‐observed	   3.5:1	   M:F	   sex	   ratio	   in	   autism.40,46,87·∙89	   Whatever	  
specific	   genetic,	   developmental	   or	   environmental	   factors	   play	   a	   role	   in	   this,	   it	   is	   clear	   that	   they	   are	  
operating	   between	   the	   time	   of	   conception	   and	   the	   end	   of	   the	   second	   year	   of	   life	   when	   most	   ASD	  
diagnoses	   are	   manifest	   and	   the	   sex	   ratio	   in	   prevalence	   is	   fully	   apparent.	   A	   distinct	   public	   health	  
consequence	  of	  non-­‐recognition	  of	  autistic	  syndromes	  in	  females	  relates	  to	  risk	  of	  transmission	  of	  ASD	  
to	   their	   own	   offspring.41,88	   Except	   for	   families	   transmitting	   known	   deleterious	   variants,	   very	   little	   is	  
known	  about	  how	   to	  estimate	   intergenerational	   transmission	   risk	   to	  women	  affected	  by	  undiagnosed	  
(sub	   clinical)	   autistic	   syndromes	   running	   in	   their	   families	   and	   expressed	   more	   prominently	  
16	  
	  
phenotypically	   in	   male	   relatives.	   Another	   factor	   that	   leads	   to	   under-­‐diagnosis	   is	   social	   disadvantage	  
(parental	  education,	   income,	  social	  economic	  status)	  and	  minority	  ethnic	  status.90·∙92	  Clinicians	  need	  to	  
be	   alert	   to	   the	   possibility	   of	   under-­‐identification	   and	   take	   special	   care	   as	   part	   of	   the	   diagnostic	  
assessment	  process	  to	  consider	  the	  needs	  of	  potentially	  disadvantaged	  groups.	  
VIII. Concluding	  comments	  
Summarized	  in	  Panel	  E	  are	  key	  considerations	  for	  a	  reconceptualization	  of	  diagnosis	  in	  autism	  informed	  




















At	  times,	  the	  process	  of	  translation	  of	  scientific	  findings	  into	  clinical	  practice	  can	  feel	  frustratingly	  slow	  
to	  clinicians	  and	  patients	  alike.	  However,	  the	  pace	  of	  discovery	  of	  our	  understanding	  of	  what	  autism	  is	  
Panel E. Re-conceptualizing diagnosis in ASD:  A summary of implications for research, clinical practice, public 
health and policy. 
A next generation of advances in nosology would be likely to improve ASD diagnosis to the extent that:  
- A refined diagnosis reflects that ASD represents the severe end of a continuous distribution of social-
communication abilities in the general population 
 
- Symptom ascertainment is standardized for sex and mental age 
 
- The interactions and expectable relationships between autistic symptomatology and other (quantitative) 
influences on child development are specified (as expectations for weight are based on height and 
standardized in the concept of body mass index) 
 
- The influences of sub clinical autistic symptoms and other dimensions of social-behavior liability that 
jointly result in clinical-level impairment in adaptive functioning can be subsumed into a coherent 
nosology without necessarily invoking the double-diagnosis of comorbidity 
 
- When identified, specific causal influences (e.g., monogenic syndromes), their unique profiles of 
behavioral disability and symptom burden, their associated symptoms (e.g., epilepsy, intellectual 
disability, ADHD) and their interactions with background (polygenic) inherited liabilities are recognized 
in the diagnostic system 
 
- Pleiotropic effects of known causes of ASD are categorized in a manner that recognizes their potential to 
influence other psychiatric syndromes 
 
- Motor coordination impairment is incorporated into sets of criteria that are sufficient to make the diagnosis 
 
- Algorithms for feasible ascertainment of developmental history, current symptom burden, and clinical 
confirmation place reliable, expedient diagnosis within reach for the majority of children in public health 
settings  
 
- Impairments in adaptive functioning attributable to the characteristic symptoms of ASD are more precisely 
specified, standardized, and implemented as standards for eligibility of service93 
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has	  been	  very	  rapid	  indeed	  over	  the	  past	  decade.	  When	  combined,	  accumulating	  information	  from	  the	  
etiological	   discoveries	   about	   what	   causes	   ASD	   in	   any	   individual,	   how	   this	   relates	   to	   the	   variability	   in	  
family	   risk	   and	   transmission,	   and	   our	   increasing	   understanding	   of	   how	   the	   clinical	   syndrome	   and	   its	  
causes	  relate	  to	  variation	  in	  ASD	  traits	  within	  the	  broader	  population,	  suggests	  that	  we	  are	  at	  a	  tipping	  
point.	  While	  many	  viewed	  the	  revisions	  to	  the	  classification	  of	  ASD	  in	  DSM-­‐5	  to	  be	  revolutionary	  –	  and	  
notwithstanding	   the	   perspective	   that	  many	   of	   them	   should	   lead	   to	   better	   clinical	   practice,	   benefiting	  
patients	  –	  translational	  discoveries	  over	  the	  next	  decade	  might	  make	  DSM-­‐6	  both	  a	  very	  interesting	  read	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